Related references
Note: Only part of the references are listed.NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
HEPATOLOGY (2020)
Non-canonical Wnt signalling regulates scarring in biliary disease via the planar cell polarity receptors
D. H. Wilson et al.
NATURE COMMUNICATIONS (2020)
Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs
Mingjun Zhang et al.
PLOS ONE (2020)
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim et al.
CANCER DISCOVERY (2019)
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
Gideon M. Hirschfield et al.
JOURNAL OF HEPATOLOGY (2019)
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Rudi Alberts et al.
GUT (2018)
The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice
Qiang Li et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2018)
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2018)
Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs
Koji Nishikawa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double Blind Placebo Controlled Trial
Marlyn J. Mayo et al.
HEPATOLOGY COMMUNICATIONS (2018)
Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15
Mei Zhou et al.
JOURNAL OF HEPATOLOGY (2017)
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Mei Zhou et al.
NATURE COMMUNICATIONS (2017)
Engineered FGF19 Eliminates Bile Acid Toxicity and Lipotoxicity Leading to Resolution of Steatohepatitis and Fibrosis in Mice
Mei Zhou et al.
HEPATOLOGY COMMUNICATIONS (2017)
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment
Masaki Kaibori et al.
ONCOTARGET (2016)
Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers
Willscott E. Naugler et al.
GASTROENTEROLOGY (2015)
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development
Iker Uriarte et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Fibroblast growth factor 15 deficiency impairs liver regeneration in mice
Bo Kong et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2014)
Protocols for staining of bile canalicular and sinusoidal networks of human, mouse and pig livers, three-dimensional reconstruction and quantification of tissue microarchitecture by image processing and analysis
Seddik Hammad et al.
ARCHIVES OF TOXICOLOGY (2014)
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Mei Zhou et al.
CANCER RESEARCH (2014)
Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys
Rama Pai et al.
TOXICOLOGICAL SCIENCES (2012)
Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
Eric T. Sawey et al.
CANCER CELL (2011)
Mouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic induction
TJ Wright et al.
DEVELOPMENTAL BIOLOGY (2004)
A mouse model of hepatocellular carcinoma - Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
K Nicholes et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Share Paper
